These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 28321811)
1. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy. Dhupkar P; Gordon N Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811 [TBL] [Abstract][Full Text] [Related]
2. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect. Kiany S; Gordon N Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675 [TBL] [Abstract][Full Text] [Related]
3. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Guma SR; Lee DA; Yu L; Gordon N; Hughes D; Stewart J; Wang WL; Kleinerman ES Pediatr Blood Cancer; 2014 Apr; 61(4):618-26. PubMed ID: 24136885 [TBL] [Abstract][Full Text] [Related]
4. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Guma SR; Lee DA; Ling Y; Gordon N; Kleinerman ES Pediatr Blood Cancer; 2014 Aug; 61(8):1362-8. PubMed ID: 24610870 [TBL] [Abstract][Full Text] [Related]
5. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428 [TBL] [Abstract][Full Text] [Related]
6. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Avanzi MP; Yeku O; Li X; Wijewarnasuriya DP; van Leeuwen DG; Cheung K; Park H; Purdon TJ; Daniyan AF; Spitzer MH; Brentjens RJ Cell Rep; 2018 May; 23(7):2130-2141. PubMed ID: 29768210 [TBL] [Abstract][Full Text] [Related]
7. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. O'Malley BW; Li D; McQuone SJ; Ralston R Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147 [TBL] [Abstract][Full Text] [Related]
8. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer. Zhang S; Zhao J; Bai X; Handley M; Shan F Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 in the treatment of renal cancer. Margolin KA Semin Oncol; 2000 Apr; 27(2):194-203. PubMed ID: 10768598 [TBL] [Abstract][Full Text] [Related]
10. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2. Chen X; Ai X; Wu C; Wang H; Zeng G; Yang P; Liu G Cell Death Dis; 2018 Sep; 9(10):989. PubMed ID: 30250191 [TBL] [Abstract][Full Text] [Related]
11. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Bernstein ZP; Porter MM; Gould M; Lipman B; Bluman EM; Stewart CC; Hewitt RG; Fyfe G; Poiesz B; Caligiuri MA Blood; 1995 Nov; 86(9):3287-94. PubMed ID: 7579429 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Donskov F Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677 [TBL] [Abstract][Full Text] [Related]
14. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293 [TBL] [Abstract][Full Text] [Related]
15. Interleukin 15 in Cell-Based Cancer Immunotherapy. Zhou Y; Husman T; Cen X; Tsao T; Brown J; Bajpai A; Li M; Zhou K; Yang L Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806311 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860 [TBL] [Abstract][Full Text] [Related]